# Scleroderma Treatment With Autologous Transplant (STAT) Study

> **NCT01413100** · PHASE2 · COMPLETED · sponsor: **Fred Hutchinson Cancer Center** · enrollment: 21 (actual)

## Conditions studied

- Systemic Scleroderma

## Interventions

- **BIOLOGICAL:** Anti-Thymocyte Globulin
- **PROCEDURE:** Autologous Hematopoietic Stem Cell Transplantation
- **DRUG:** Cyclophosphamide
- **BIOLOGICAL:** Filgrastim
- **OTHER:** Laboratory Biomarker Analysis
- **DRUG:** Mycophenolate Mofetil
- **PROCEDURE:** Peripheral Blood Stem Cell Transplantation
- **DRUG:** Plerixafor
- **OTHER:** Quality-of-Life Assessment
- **OTHER:** Questionnaire Administration

## Key facts

- **NCT ID:** NCT01413100
- **Lead sponsor:** Fred Hutchinson Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2011-09-15
- **Primary completion:** 2023-09-15
- **Final completion:** 2024-09-11
- **Target enrollment:** 21 (ACTUAL)
- **Last updated:** 2025-01-07

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01413100

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01413100, "Scleroderma Treatment With Autologous Transplant (STAT) Study". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT01413100. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*